Monthly Archives: November 2011
Tiered Pricing Not Always a Win-Win
Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.
Posted in Corporate Responsibility, Emerging Markets, Global, IP, Manufacturing, Market Access, R&D, Strategy, pricing 2 Comments
The Real Way to Lean Success: Suck Out the IT Fat
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat, writes Bill Drummy.
Consider this: In 2011, IMS projects US Rx market growth to be 2.7 percent. The top 10 pharma companies account for 50 percent of the entire market’s revenue, but will deliver only 10 percent of the [...]

A Simple Plan (to Save US Pharma Manufacturing)